Wegovy lowers blood pressure: what the clinical evidence actually shows

What the STEP trials measured and what the numbers mean

The STEP 1 trial, which enrolled 1,961 adults with obesity or overweight and at least one weight-related condition (but without type 2 diabetes), showed an average systolic blood pressure fall of around 6 mmHg and a diastolic reduction of roughly 2–3 mmHg in participants receiving semaglutide 2.4 mg weekly. These figures are from the published trial data cited by the NICE technology appraisal of semaglutide (TA875), which recommended Wegovy for weight management in the UK in 2023. A 6 mmHg reduction in systolic blood pressure may sound modest, but population studies consistently show that sustained reductions of that size are associated with meaningfully lower stroke and heart attack risk over time. The blood pressure benefit was most pronounced in participants who also achieved the greatest weight loss, which points to weight reduction as a major driver. That said, GLP-1 receptor agonists like semaglutide, a medicine with a growing body of evidence behind it, are thought to have additional effects on vascular inflammation and sympathetic nervous system activity that may contribute independently of weight change. The trials were not designed to isolate these mechanisms, they measured outcomes, not pathways. What clinicians can say confidently is that the cardiovascular signal is real and that regulators took it seriously enough to grant semaglutide a separate UK indication specifically for reducing the risk of major cardiovascular events in adults with established heart disease and a BMI of 27 or above.

Why blood pressure improves: weight loss, the GLP-1 pathway and the heart

Excess weight raises blood pressure through several overlapping routes: it increases circulating blood volume, stiffens arterial walls, raises levels of inflammatory markers, and tends to activate the sympathetic nervous system. Losing a meaningful proportion of body weight reverses several of these processes simultaneously. The NHS semaglutide medicines page explains how semaglutide works as a GLP-1 receptor agonist, slowing gastric emptying, reducing appetite signals in the brain, and improving glucose handling, all of which contribute to sustained weight reduction. Beyond weight, GLP-1 receptors are found on blood vessel walls and in cardiac tissue, and preclinical studies suggest direct vasodilatory effects, though the clinical importance of this in humans is still being quantified. The practical takeaway: if you are already taking antihypertensive medication and you begin losing weight on Wegovy, your blood pressure readings may fall further than expected. This is generally a positive development, but it does mean your prescribing team should monitor your readings and may need to review your antihypertensive dose over time. Adjusting blood pressure medication is a clinical decision, your GP or prescriber is the right person to make that call, not a home monitor. For a broader look at how Wegovy affects blood pressure across different cardiovascular markers, the full overview of Wegovy and blood pressure covers the cardiovascular indication in more detail.

Who this applies to and what to discuss with a prescriber

Not everyone experiences the same degree of blood pressure reduction. Several factors influence the response: baseline blood pressure, starting weight, degree of weight loss achieved, individual cardiovascular history, and concurrent medications. People with higher baseline systolic readings tend to show larger absolute reductions, which follows logically, there is more room to fall. Those already at normal blood pressure are unlikely to develop clinically significant hypotension from Wegovy alone, though the combination with antihypertensive medicines warrants monitoring. Semaglutide is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Hypertension is itself one of the qualifying conditions, so many people starting Wegovy already have elevated readings. If you are exploring treatment options and want to understand the risk of blood pressure going too low on semaglutide, that is worth reading before your consultation. The prescriber reviewing your case will look at your current medication list, your cardiovascular history, and your blood pressure readings as part of the assessment. That is not bureaucracy, it is the check that keeps the treatment safe. You can also review the range of weight-loss treatments we support to see where Wegovy fits alongside other licensed options.

Reporting concerns and staying safe during treatment

If you notice symptoms that could suggest blood pressure changes (lightheadedness on standing, persistent headaches, or palpitations) tell your prescriber promptly rather than waiting for a scheduled review. These symptoms are not common with Wegovy but they are worth reporting, particularly in the early weeks of treatment or after a dose increase. The MHRA's Yellow Card scheme allows patients and healthcare professionals to report any suspected side effects from a medicine; this data feeds directly into ongoing safety monitoring for all GLP-1 medicines in the UK. Blood pressure monitoring at home is sensible and easy, but readings should be shared with your clinical team rather than acted on unilaterally. The interaction between weight-loss medicines and antihypertensive drugs is well recognised and manageable with the right oversight. For more detail on whether Wegovy genuinely lowers blood pressure and what the evidence shows, the evidence summary for Wegovy and blood pressure benefit goes deeper into the cardiovascular trial data. If you think Wegovy might be appropriate for you, speaking to our prescribers is the starting point, the consultation is free, and your answers are reviewed the same day by a named GPhC-registered clinician.